Overview

An Eight-week Study Evaluating the Efficacy and Tolerability of Two Doses of SSR149415 in Outpatients With Generalized Anxiety Disorder

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:

Participant gender:

Summary

The objective is to evaluate the efficacy and safety of two doses of SSR149415 (250 mg and 100 mg twice daily) compared to placebo and paroxetine 20 mg once daily in outpatients with generalized anxiety disorder

Phase:

Phase 2

Details

Lead Sponsor:

Sanofi

Treatments:

Paroxetine